Business Wire

Capital A Leverages Ant International’s AI-Enabled FX Solution to Optimise Treasury Operations and Enhance Customer Experience

7.10.2025 05:00:00 CEST | Business Wire | Press Release

Share

Capital A has partnered with Ant International to optimise treasury operations and enhance customer experience for its airline business, AirAsia. By leveraging Ant International’s proprietary Falcon Time-Series Transformer (TST) Model, Capital A was able to better manage AirAsia's cash flows across multiple currencies and in turn, offer more stable, competitive pricing to its customers.

This was enabled by Falcon, which enhanced AirAsia’s FX risk management and reduced its hedging costs by up to 40%, allowing the airline to pass the cost savings on to customers through more competitive FX rates. The integration also resulted in a more future-proof and scalable treasury management solution for AirAsia, with 90% accuracy in forecasting the company's cashflow and FX exposure on an hourly, daily and weekly basis.

This integration marks the first industry-tailored solution that Ant International has developed from Falcon. Following the launch in April, Ant applied the large data model to various treasury management scenarios to design solutions for specialised industries, such as airlines. The model was trained on 2 billion parameters, including 80 million parameters of travel-related data, such as open-sourced data from OTAs and air carriers. This enabled Ant to launch an AI FX offering catered to the airline industry.

The solution was then integrated with Capital A’s corporate banking partner’s fixed FX rate infrastructure to complete transactions for AirAsia. Ant International estimates that in time, the enhanced solution could help the broader airline industry reduce its overall FX costs by as much as 60% for selected currency pairs.

Aireen Omar, Group Chief Executive Officer, BigPay, said: “As a group, we serve over 70 million travellers yearly, 35 million AirAsia Rewards members and our fintech arm, BigPay has over 1.6 million carded users. Through our partnership with Ant International, we are able to reduce the hedging cost by 40%. This helps us immensely as Capital A processes massive multicurrency volumes every day and this platform updates FX rates twice daily and provides great margin management capability.

Kelvin Li, General Manager of Platform Tech at Ant International, said: “Our partnership with Capital A marks the first commercial deployment of Falcon, an important milestone in our journey to transform treasury and FX management for businesses. The results demonstrate how innovation, technology and institutional-grade execution solve real-world FX challenges and reshape cross-border payments. We look forward to serving more businesses and industries as we continue to build on our enterprise embedded finance solutions.”

According to a report from McKinsey1, the airline industry processes about 2.9 billion payment transactions annually, valued at $1 trillion. Despite the scale of payment processing the sector is involved in, there is a lack of tailored solutions from the payments industry that enable airlines to lower its associated payment costs. Airlines spend over $20 billion annually on payment-related expenses, accounting for 3% of the industry’s total revenue.

With airline travel set to continue growing to 5.2 billion passengers this year as estimated by IATA, Capital A and Ant International recognise the need for enhanced solutions that will allow the industry to improve their FX risk management and lower costs, by leveraging AI. Both sides will continue to explore more efficient and transparent global fund management solutions via Ant International's Bettr Treasury Platform.

About Capital A

Capital A is an investment holding company with a diverse portfolio of synergistic aviation and travel businesses, leveraging data and technology to drive growth. Our key businesses include AirAsia, the world’s leading low-cost carrier, Capital A Aviation Services Group, AirAsia MOVE (formerly airasia Superapp) and fintech BigPay as well as logistics venture Teleport and brand development company, Abc. Capital A’s vision is to create and deliver products and services that focus on offering the best value at the lowest cost, underpinned by robust data accumulated over 20 years in operation and one of Asia's leading brands that remains committed to serving the underserved in Asean and beyond.

About Ant International

With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/

1 Airline retailing: How payment innovation can improve the bottom line (2022) https://www.mckinsey.com/industries/travel/our-insights/airline-retailing-how-payment-innovation-can-improve-the-bottom-line

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006353902/en/

Contacts

Media Contacts

Capital A
Tashya Viknesh
press@bigpayme.com

Ant International
Kahmun Leong
kahmun.leong@ant-intl.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye